Vesper Bio is a private, VC-backed, clinical stage company with world-leading domain expertise in Vps10p domain receptors.
Vesper Bio is developing a rich pipeline of first-in-class small molecule sortilin modulators for a number of critical unmet medical needs. Alongside our lead program, VES001 for FTD-GRN, we are leveraging our deep domain expertise in sortilin biology to explore multiple additional targets with high disease relevance in a number of therapy areas and indications.